Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Munich - Delayed Quote • EUR Omeros Corp (3O8.MU) Follow Add holdings 6.20 -0.07 (-1.04%) As of 8:08:07 AM GMT+2. Market Open. Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 3O8.MU 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: 3O8.MU View More All News Press Releases SEC Filings Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases Q4 2024 Omeros Corp Earnings Call Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ... Omeros: Q4 Earnings Snapshot Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025 Omeros to activate site for Phase III programme of zaltenibart for PNH Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder Omeros announces results for narsoplimab expanded access program